Craft

G1 Therapeutics

Stock Price

$3.3

2024-03-19

Market Capitalization

$171.2 M

2024-03-19

Revenue

$82.5 M

FY, 2023

G1 Therapeutics Summary

Company Summary

Overview
G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. It offers COSELA, a product that helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small-cell lung cancer. The company also develops trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor for patients with first-line colorectal cancer and neoadjuvant breast cancer. G1 Therapeutics also offers rintodestrant, an oral selective estrogen receptor degrader (SERD) in development for the treatment of estrogen receptor-positive (ER+) breast cancer.
Type
Public
Status
Active
Founded
2008
HQ
Durham, NC, US | view all locations
Website
https://www.g1therapeutics.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Mark Avagliano

    Mark Avagliano, Chief Business Officer

  • Jennifer Moses

    Jennifer Moses, Chief Financial Officer

  • James Stillman Hanson

    James Stillman Hanson, General Counsel

    • Terry Murdock

      Terry Murdock, Chief Operating Officer

    Operating MetricsView all

    Patent Families

    30

    FY, 2020

    Patents and Patent Applications

    350

    FY, 2020

    Patents (US)

    40
    29.0%

    FY, 2020

    LocationsView all

    1 location detected

    • Durham, NC HQ

      United States

      400 Park Offices Dr Suite 218

    G1 Therapeutics Financials

    Summary Financials

    Revenue (FY, 2023)
    $82.5M
    Net income (FY, 2023)
    ($48.0M)
    Cash (FY, 2023)
    $32.2M
    EBIT (FY, 2023)
    ($39.5M)
    Enterprise value
    $199.1M

    Footer menu